RxDoctor Payments Data

Jennifer Kern, DPM

Podiatrist · West Columbia, SCNPI 1568402790

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.8% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Averitas Pharma Inc. at 31.3% of the total.

$2,400in general payments, 2019–2025

Across 116 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Averitas Pharma Inc.$750
  • Organogenesis Inc.$527
  • Paratek Pharmaceuticals, Inc.$340
  • Smith+Nephew$157
  • AbbVie$134
  • Treace Medical Concepts, Inc.$116
  • plus $376 from 10 others

What the payments were for

  • Consulting fees$1004%
  • Food & beverage$2,30096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Averitas Pharma Inc.35$750
Organogenesis Inc.20$527
Paratek Pharmaceuticals, Inc.22$340
Smith+Nephew9$157
AbbVie7$134
Treace Medical Concepts, Inc.3$116
Comsort, Inc1$100
Kerecis Limited2$66
GRT US Holding, Inc.6$59
Peerless Surgical Inc.2$48
Ortho Dermatologics, A Division Of Bausch Health US, LLC2$34
Glenmark Therapeutics Inc.2$24
Alfasigma USA, Inc.1$16
Sandoz1$15
Merck1$9
Prugen, Inc. Pharmaceuticals2$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,400 in reported general payments places this provider in the 70th percentile of 61 podiatrist providers in South Carolina.

See all podiatrist providers in South Carolina

Medicare billing

Part B allowed, 2024
$565,619
Medicare patients
693
Services billed
78,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mupirocin94$655
Ketoconazole13$283
Gabapentin13$166
Doxycycline Hyclate14$139
Cephalexin28$123
Allopurinol15$113
Meloxicam19$75

Paid to pharmacies, not to this prescriber.

Other podiatrist in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →